William Blair Maintains Their Buy Rating on Assembly Biosciences (ASMB)

By Ryan Adsit

William Blair analyst Raju Prasad maintained a Buy rating on Assembly Biosciences (ASMBResearch Report) today. The company’s shares closed last Thursday at $20.85.

According to TipRanks.com, Prasad is a 5-star analyst with an average return of 15.4% and a 57.6% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.

Currently, the analyst consensus on Assembly Biosciences is a Strong Buy with an average price target of $43.00.

See today’s analyst top recommended stocks >>

Based on Assembly Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $4.08 million and GAAP net loss of $26.66 million. In comparison, last year the company earned revenue of $3.08 million and had a GAAP net loss of $18.5 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.